Northfield Laboratories Inc. to Receive Defense Appropriation for PolyHeme(R) Development
January 03 2006 - 2:17PM
PR Newswire (US)
EVANSTON, Ill., Jan. 3 /PRNewswire-FirstCall/ -- Northfield
Laboratories Inc. (NASDAQ:NFLD) announced today that it will
receive $3.5 million in designated funding for the continued
development of PolyHeme(R), the Company's human hemoglobin-based
oxygen carrier, as part of the Fiscal 2006 Defense Appropriations
Bill recently signed by President Bush. "Northfield is pleased to
be included in the federal government's defense appropriation
budget once again. We would like to extend our sincere appreciation
to Senator Richard Durbin of Illinois and his staff for their
support and leadership in securing this funding for our work," said
Steven A. Gould, M.D., Chairman and Chief Executive Officer.
Durbin, the Assistant Democratic Leader, is a member of the Senate
Appropriations Committee and secured the funding in the Fiscal Year
2006 Defense Appropriations bill. He visited Northfield's Mt.
Prospect manufacturing facility earlier today. "This research has
the potential to save lives," said Durbin. "First responders will
be better able to help injured persons with massive blood loss and
surgeons will have another resource in the emergency room. PolyHeme
could also help doctors in rural or remote settings where blood
supplies for transfusions are limited." About Northfield
Laboratories Northfield Laboratories Inc. is a leader in developing
an oxygen-carrying resuscitative fluid, PolyHeme(R), for the
treatment of urgent, large volume blood loss in trauma and
resultant surgical settings. PolyHeme(R) is a solution of
chemically modified human hemoglobin that requires no cross
matching and is therefore compatible with all blood types. It has a
shelf life of over 12 months. Enrollment is currently underway in a
pivotal Phase III study of PolyHeme(R) beginning in the
pre-hospital setting. For further information about Northfield
Laboratories, visit http://www.northfieldlabs.com/ This press
release contains forward-looking statements concerning, among other
things, Northfield's future business plans and strategies and
clinical and regulatory developments affecting our PolyHeme blood
substitute product. These forward-looking statements are identified
by the use of such terms as "intends," "expects," "plans,"
"estimates," "anticipates," "should," "believes" and similar terms.
These forward-looking statements involve inherent risks and
uncertainties. Our actual results may therefore differ materially
from those predicted by the forward-looking statements because of
various factors and possible events, including our ability to
obtain FDA approval to market PolyHeme commercially, the
availability of capital to finance our clinical trials and ongoing
business operations, our ability to obtain adequate supplies of raw
materials and to manufacture PolyHeme in commercial quantities, our
ability to market PolyHeme successfully, the possibility that
competitors will develop products that will render PolyHeme
obsolete or non-competitive, our ability to protect our
intellectual property rights, the possibility that we may be
subject to product liability claims and other legal actions, our
dependency on a limited number of key personnel, the uncertainty of
Fourth, Final party reimbursement for our product and other risks
and uncertainties described from time to time in our periodic
reports filed with the Securities and Exchange Commission,
including our most recently filed quarterly report on Form 10-Q and
annual report on Form 10-K. These forward-looking statements speak
only as of the date of this press release. We do not undertake any
obligation to update or publicly release any revisions to
forward-looking statements to reflect events, circumstances or
changes in expectations after the time such statement is made. All
subsequent written and oral forward-looking statements attributable
to Northfield or any person acting on our behalf are qualified by
this cautionary statement. FOR FURTHER INFORMATION CONTACT: Sophia
H. Twaddell Sharon L. Weinstein Vice President, Corporate
Communications Noonan Russo (847) 864-3500 (212) 845-4271
DATASOURCE: Northfield Laboratories Inc. CONTACT: Sophia H.
Twaddell, Vice President, Corporate Communications of Northfield
Laboratories Inc., +1-847-864-3500, , or Sharon L. Weinstein of
Noonan Russo, +1-212-845-4271, Web site:
http://www.northfieldlabs.com/
Copyright
Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Jul 2023 to Jul 2024